San Jose, California (PRWEB) August 14, 2013
Follow us on LinkedIn – Worldwide influenza vaccine sales skyrocketed in the year 2009 with the introduction of vaccines to tackle the Influenza A (H1N1) pandemic virus. However, the momentum provided by the dreaded Swine Flu, ran out of steam by August 2010, with the World Health Organization (WHO) officially declaring the disease to have entered the post-pandemic stage. Nevertheless, the WHO continues to monitor outbreaks and prevalence of the H1N1 flu virus. Small outbreaks in Influenza A (H1N1)pdm09 virus were reported in certain countries of Asia, Africa, Europe, South America, as well as Central America in the post-pandemic phase. The Influenza A (H1N1)pdm09 virus is considered responsible for all the seasonal activity of (H1N1) A viruses between September 2012 and January 2013.
As a precautionary measure, WHO recommends manufacturers to include strain of A/California/7/2009 (H1N1)pdm09-like virus in the formulation of in-house seasonal influenza vaccines. Based on the WHO advisory, several governments across the globe continue to stock up on monovalent H1N1 vaccines to prevent another outbreak of the disease, besides immunizing the general population with trivalent and quadrivalent seasonal influenza vaccines, containing the analogous strain of the 2009 H1N1 virus in accordance with the availability and affordability of the vaccines in each geographic region.
The recent advancements in cell-culture and recombinant technologies are boosting the speed and efficiency of the vaccine production processes. However, the traditional egg-based production method remains the most widely used method for vaccine preparation. This method however requires larger time-frames and thereby result in inadequate supply of the necessary vaccines in case of a sudden pandemic attack. New strains of viruses resulting from antigenic shift of the A/California/7/2009 (H1N1)pdm09 virus, usually occurring when the virus is being passed on from animal to animal or a human being, also stresses the need to develop more effective vaccines. However, manufacturers face a daunting challenge in the form of the huge costs involved in vaccine development, clinical trials, regulatory approval, mass production, and commercialization.
North America accounts for the largest share of H1N1 vaccine sales worldwide, as stated by the new market research report on H1N1 Vaccines. Rapid growth in birth cohorts in developing countries, coupled with the improvement in access to public and private healthcare and increased spending, entail a growing demand for vaccines in the developing world. Notably, the 2009 H1N1 pandemic resulted in widespread panic in China and India, partly due to the respective government’s unpreparedness to handle the disease outbreak. The governments in these countries are expected to continue domestic production and stockpiling of reserve H1N1 vaccine doses in the near term. Increasing public awareness about influenza vaccines, coupled with the need to safeguard the population in the event of a future outbreak, will continue to drive sales of H1N1 vaccines.
Key players covered in the report include Baxter International Inc., CPL Biologicals Pvt. Ltd., CSL Limited, bioCSL, GlaxoSmithKline Plc., MedImmune LLC, Novartis AG, Sanofi Pasteur SA, Sinovac Biotech Ltd., and Zydus Cadilla.
The research report titled “H1N1 Vaccines: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides an in-depth study of the key factors influencing the performance of H1N1 influenza vaccines market, pertinent macro and micro market trends, key growth drivers and inhibitors, and recent strategic corporate initiative. The report also provides revenue estimates and forecasts for H1N1 vaccines in US$ million for the four major geographic regions including North America, Europe, Asia-Pacific, and Rest of World.
For more details about this comprehensive market research report, please visit – http://www.strategyr.com/H1N1_Vaccines_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/
Read the full story at http://www.prweb.com/releases/H1N1_vaccines_market/swine_flu_virus/prweb11026598.htm.
Copyright©2012 Vocus, Inc.
All rights reserved